Trial Profile
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Vadadustat (Primary)
- Indications Anaemia; Renal failure
- Focus Therapeutic Use
- Sponsors Akebia Therapeutics
- 28 Mar 2017 According to an Akebia Therapeutics media release, results was published online by the American Journal of Nephrology.
- 28 Mar 2017 Results published in an Akebia Therapeutics media release.
- 13 Aug 2014 New trial record